Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 5, 2014, Pages 1195-1203

  Ross, Ted M ^a,f   Lin, Chyongchiou Jeng ^b   Nowalk, Mary Patricia ^b   Huang, Hsin Hui ^b   Spencer, Sarah M ^e   Shay, David K ^e   Sambhara, Suryaprakash ^e   Sundaram, Maria E ^c   Friedrich, Thomas ^d,h   Sauereisen, Sandy ^g   Bloom, Chalise E ^a,f   Zimmerman, Richard K ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MARSHFIELD CLINIC   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^f Vaccine and Gene Therapy Institute of Florida   (United States)

^g St Margaret Memorial Hospital   (United States)

^h UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antibodies; Human influenza; Immune response; Immunogenicity

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HEMAGGLUTINATION INHIBITION; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); MALE; PROTECTION; RACE DIFFERENCE; SEROCONVERSION; SEX DIFFERENCE; VIRUS STRAIN; AGE; ANTIBODY PRODUCTION; CLINICAL TRIAL; DRUG EFFECTS; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA VIRUS A H3N2; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; ANTIBODY FORMATION; FEMALE; HEMAGGLUTINATION; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; VACCINES, INACTIVATED;

EID: 84901400888     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.28313     Document Type: Article

References (33)

1. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40; PMID:15367555; http://dx.doi.org/10.1001/jama.292.11.1333
2. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36; PMID:22495079; http://dx.doi.org/10.1093/cid/cis211
3. Centers for Disease Control and Prevention (CDC). Estimates of deaths associated with seasonal influenza - United States, 1976-2007. MMWR Morb Mortal Wkly Rep 2010; 59:1057-62; PMID:20798667
4. Topham DJ, Tripp RA, Doherty PC. CD8+ T cells clear influenza virus by perforin or Fas-dependent processes. J Immunol 1997; 159:5197-200; PMID:9548456
5. Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 2006; 24:1159-69; PMID:16213065; http://dx.doi.org/10.1016/j.vaccine.2005.08.105
6. Powers DC, Belshe RB. Effect of age on cytotoxic T lymphocyte memory as well as serum and local antibody responses elicited by inactivated influenza virus vaccine. J Infect Dis 1993; 167:584-92; PMID:8440930; http://dx.doi.org/ 10.1093/infdis/167.3.584
7. Centers for Disease Control and Prevention (CDC). Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013. MMWR Morb Mortal Wkly Rep 2013; 62:119-23; PMID:23425960
8. Webster RG. Immunity to influenza in the elderly. Vaccine 2000; 18:1686-9; PMID:10689149; http://dx.doi.org/10.1016/S0264-410X(99)00507-1
9. Lessler J, Riley S, Read JM, Wang S, Zhu H, Smith GJ, Guan Y, Jiang CQ, Cummings DA. Evidence for antigenic seniority in influenza A (H3N2) antibody responses in southern China. PLoS Pathog 2012; 8:e1002802; PMID:22829765; http://dx.doi.org/10.1371/journal.ppat.1002802
10. Sasaki S, Jaimes MC, Holmes TH, Dekker CL, Mahmood K, Kemble GW, Arvin AM, Greenberg HB. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007; 81:215-28; PMID:17050593; http://dx.doi.org/10.1128/JVI.01957-06
11. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008; 453:667-71; PMID:18449194; http://dx.doi.org/10.1038/nature06890
12. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc Natl Acad Sci U S A 2012; 109:9047-52; PMID:22615367; http://dx.doi.org/10. 1073/pnas.1118979109
13. Ellebedy AH, Ahmed R. Re-engaging cross-reactive memory B cells: the influenza puzzle. Front Immunol 2012; 3:53; PMID:22566934; http://dx.doi.org/10. 3389/fimmu.2012.00053
14. O'Donnell CD, Wright A, Vogel LN, Wei CJ, Nabel GJ, Subbarao K. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol 2012; 86:8625-33; PMID:22674976; http://dx.doi.org/10.1128/JVI.00147-12
15. Song JY, Cheong HJ, Hwang IS, Choi WS, Jo YM, Park DW, Cho GJ, Hwang TG, Kim WJ. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence. Vaccine 2010; 28:3929-35; PMID:20394719; http://dx.doi.org/10.1016/j.vaccine.2010.03.067
16. Bucasas KL, Franco LM, Shaw CA, Bray MS, Wells JM, Niño D, Arden N, Quarles JM, Couch RB, Belmont JW. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J Infect Dis 2011; 203:921-9; PMID:21357945; http://dx.doi.org/10.1093/infdis/jiq156
17. Franco LM, Bucasas KL, Wells JM, Niño D, Wang X, Zapata GE, Arden N, Renwick A, Yu P, Quarles JM, et al. Integrative genomic analysis of the human immune response to influenza vaccination. eLife 2013; 2:e00299; PMID:23878721; http://dx.doi.org/10.7554/eLife.00299
18. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459:931-9; PMID:19525932; http://dx.doi.org/10.1038/nature08157
19. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201; PMID:19465683; http://dx.doi.org/10.1126/science.1176225
20. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52; PMID:19745214; http://dx.doi.org/10.1056/NEJMoa0906453
21. Beyer WE, Palache AM, Sprenger MJ, Hendriksen E, Tukker JJ, Darioli R, van der Water GL, Masurel N, Osterhaus AD. Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults. Vaccine 1996; 14:1331-9; PMID:9004442; http://dx.doi.org/10.1016/S0264-410X(96)00058-8
22. Seidman JC, Richard SA, Viboud C, Miller MA. Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza Other Respir Viruses 2012; 6:52-62; PMID:21668661; http://dx.doi.org/10.1111/j.1750- 2659.2011.00268.x
23. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1128-32; PMID:21866086
24. Gillim-Ross L, Subbarao K. Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev 2006; 19:614-36; PMID:17041137; http://dx.doi.org/10.1128/CMR.00005-06
25. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 2005; 366:1175-81; PMID:16198766; http://dx.doi.org/10.1016/ S0140-6736(05)67338-2
26. Bright RA, Ross TM, Subbarao K, Robinson HL, Katz JM. Impact of glycosylation on the immunogenicity of a DNA-based influenza H5 HA vaccine. Virology 2003; 308:270-8; PMID:12706077; http://dx.doi.org/10.1016/S0042- 6822(03)00008-4
27. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-4; PMID:16456087; http://dx.doi.org/10.1001/ jama.295.8.joc60020
28. Mitchell JA, Green TD, Bright RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 2003; 21:902-14; PMID:12547601; http://dx.doi.org/10. 1016/S0264-410X(02)00539-X
29. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1:127-31; PMID:11248804; http://dx.doi.org/10.1038/77802
30. U.S. Department of Health and Human Services. Guidance for Industry: Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines. Silver Spring, MD, 2007.
31. Cochran WG. Some Methods for Strengthening the Common χ2 Tests. Biometrics 1954; 10:417-51; http://dx.doi.org/10.2307/3001616
32. Armitage P. Tests for Linear Trends in Proportions and Frequencies. Biometrics 1955; 11:375-86; http://dx.doi.org/10.2307/3001775
33. Liu H. Cochran-Armitage Trend Test for Using SAS. SAS Institute Inc, 2004.